United States Cellular Corporation 6.250% Senior Notes due 2069 Azioni (NYSE: UZD)

Ultime notizie per United States Cellular Corporation 6.250% Senior Notes due 2069 (NYSE:UZD) Azioni

United States Cellular Corporation 6.250% Senior Notes due 2069

RTX shares are trading lower after the company issued FY25 revenue guidance below estimates.

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintains Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) with a Outperform and raises the price target from $90 to $150.

News

Price Target

Analyst Ratings

ROOT

Keefe, Bruyette & Woods Maintains Outperform on Root, Raises Price Target to $150

Buybacks

OBLG

Oblong Announces It Has Authorized A Stock Buyback Program To Repurchase Up To $500K Of The Company's Common Stock

JMP Securities analyst Nicholas Jones reiterates Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Market Outperform and maintains $150 price target.

Reiteration

ADUS

JMP Securities Reiterates Market Outperform on Addus HomeCare, Maintains $150 Price Target

Macro Economic Events

Econ #s

Economics

CORRECTION: USA Redbook (YoY) 7.4% Vs 6.6% Prior

Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) shares are trading lower on Tuesday in the premarket session after the company <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">reported first-quarter results.</a>
Quarterly adjusted earnings per share totaled $1.93, beating<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44918244/kimberly-clark-announces-first-quarter-2025-results-and-updates-2025-outlook" rel="noreferrer noopener"> the analyst consensus estimate of $1.89.</a> Quarterly sales of $4.84 billion (down 6%) missed the street view of $4.88 billion.
&#8220;The current environment will now mean greater costs across our global supply chain versus our expectations at the beginning of the year,&#8221; warned Kimberly-Clark CEO Mike Hsu. 
North America reported net sales of $2.7 billion for the quarter, reflecting a year-over-year decline of 3.9%.
International Personal Care net sales came in at $1.4 billion, down 8.9%, while International Family Products sales totaled $791 million, marking a 7.7% decrease.
Sales fell due to currency impacts, divestitures, and business exits, with an organic sales decline of 1.6% compared to the prior year.
Also Read: <a href="https://www.benzinga.com/25/04/44916944/us-stocks-likely-to-open-higher-amid-trumps-preemptive-rate-cut-call-earnings-are-starting-to-reflect-this-uncertainty-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Higher Amid Trump&#8217;s Preemptive Rate Cut Call</a>
The quarterly&nbsp;adjusted gross margin was 36.9%, down 20 basis points compared to the prior year.
The company&#8217;s adjusted operating profit was $844 million. That&#8217;s down 6% versus the prior year, inclusive of an unfavorable impact from currency translation of 2.2%.
Cash and equivalents at quarter end was $563 million, and inventories totaled $1.909 billion.
Total debt was&nbsp;$7.2 billion&nbsp;as of&nbsp;March 31, 2025, down from&nbsp;$7.4 billion&nbsp;as of&nbsp;December 31, 2024.
Outlook: The company now expects its 2025 Adjusted Operating Profit to be flat to positive on a constant-currency basis. Last year, the expectation was high single-digit growth on a constant currency basis.
Reported net sales are expected to face a 200 basis point hit from currency translation, improving from the earlier estimate of 300 basis points. Additionally, divesting the PPE business and exiting the U.S. private label diaper segment will weigh on sales by another 240 basis points.
Adjusted Earnings Per share are now expected to be flat to positive on a constant-currency basis.
The company also expects adjusted free cash flow to be around $2 billion in 2025. That&#8217;s slightly lower than its earlier forecast of over $2 billion.
Price Action: KMB shares are trading lower by 4.26% to $134.10 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44916388/chicago-fed-chair-goolsbee-agrees-with-bessent-fed-independence-is-a-jewel-box-awaits-tariff-revisit-before-jumping-to-action" target="_blank" rel="noreferrer noopener">Chicago Fed Chair Goolsbee Agrees With Bessent: ‘Fed Independence Is A Jewel Box,' Awaits Tariff Revisit Before ‘Jumping To Action'</a></li>
</ul>
Image: Shutterstock

Earnings

Equities

Guidance

Markets

Movers

General

Kimberly-Clark Misses Q1 Revenue Mark, Trims Profit Guidance As Supply Chain Costs Bite Hard

Wells Fargo analyst Michael Turrin maintains Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) with a Equal-Weight and lowers the price target from $640 to $610.

Wells Fargo Maintains Equal-Weight on Tyler Technologies, Lowers Price Target to $610

Keefe, Bruyette &amp; Woods analyst Tommy McJoynt maintains MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) with a Outperform and lowers the price target from $19 to $16.

Keefe, Bruyette & Woods Maintains Outperform on MediaAlpha, Lowers Price Target to $16

WIIM

Boeing shares are trading higher after the company announced it will sell portions of its Digital Aviation Solutions business to Thoma Bravo for $10.55 billion in an all-cash transaction.

New reporting will not impact scores in near-term, but advances efforts to help consumers build credit histories and support positive credit outcomes

AFRM

Affirm Holdings Expands Credit Reporting With TransUnion; All Affirm Pay-Over-Time Loans To Be Reported To TransUnion

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=54241486&amp;newsitemid=20250422501694&amp;lan=en-US&amp;anchor=Veracyte%2C+Inc&amp;index=1&amp;md5=14ab75ff8f2393b4488c836f365cf578">Veracyte, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2025, the annual meeting of the American Urological Association, taking place April 26-29 in Las Vegas. Study findings to be presented include new data from the use of the Decipher tests in clinical trials as well as insights into these cancers' underlying biology, which researchers derived through use of the whole-transcriptome-based Decipher GRID (Genomic Resource for Intelligent Discovery) research tool.

VCYT

Veracyte Says At Least 18 Abstracts Focused On Decipher Prostate And Decipher Bladder Genomic Classifiers Will Be Presented At AUA 2025

Shengfeng Development Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFWL#NASDAQ">SFWL</a>) ("Shengfeng" or the "Company"), a leading integrated logistics solutions provider in China, today announced a multi-year strategic partnership with Contemporary Amperex Technology Co., Limited (CATL) (SZSE: 300750), a global leader in lithium-ion battery innovation (the "Partnership"). The collaboration which is expected to be valued at approximately 300 million RMB ($42 million USD), reinforces Shengfeng's pivotal role in advancing CATL's global clean energy supply chain and underscores its leadership in China's rapidly evolving new energy logistics sector.

Contracts

SFWL

Shengfeng Development Enters Multi-Year Strategic Partnership With Contemporary Amperex Technology. Collaboration Is Expected To Be Valued At ~$42M

Wells Fargo analyst Michael Turrin maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Overweight and lowers the price target from $160 to $120.

TWLO

Wells Fargo Maintains Overweight on Twilio, Lowers Price Target to $120

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintains Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) with a Underperform and lowers the price target from $25 to $22.

LMND

Keefe, Bruyette & Woods Maintains Underperform on Lemonade, Lowers Price Target to $22

Asset Sales

Boeing To Sell Portions Of Its Digital Aviation Solutions To Thoma Bravo For $10.55B In All-Cash Transaction

Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ovintiv, revealing an average target of $50.4, a high estimate of $59.00, and a low estimate of $45.00. Experiencing a 0.2% decline, the current average is now lower than the previous average price target of $50.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1745326884_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Ovintiv among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Roger Read &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $46.00&#x7C;$45.00 &#x7C; 
&#x7C;Devin McDermott &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Overweight &#x7C; $57.00&#x7C;- &#x7C; 
&#x7C;Roger Read &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $45.00&#x7C;$44.00 &#x7C; 
&#x7C;Arun Jayaram &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $45.00&#x7C;$56.00 &#x7C; 
&#x7C;Betty Jiang &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $59.00&#x7C;$57.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ovintiv. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ovintiv compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ovintiv's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Ovintiv's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/OVV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ovintiv analyst ratings.</a>
<h2>Delving into Ovintiv's Background</h2>
Ovintiv Inc is a North American oil and natural gas exploration and production company that is focused on developing its multi-basin portfolio of high-quality assets located in the United States and Canada. Its operations also include the marketing of oil, NGLs and natural gas. The company has two operating segments: USA Operations, and Canadian Operations. The USA Operations include the exploration for, development of, and production and marketing of oil, NGLs, natural gas and other related activities within the United States. The Canadian Operations include the exploration for, development of, and production and marketing of oil, NGLs, natural gas and other related activities within Canada.
<h3>Ovintiv's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Ovintiv's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -30.89% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Ovintiv's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -2.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.57%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ovintiv's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.31%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Ovintiv's debt-to-equity ratio is below the industry average at 0.61, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Ovintiv: Insights From 5 Analyst Reviews

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintains Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) with a Market Perform and raises the price target from $24 to $26.

HIPO

Keefe, Bruyette & Woods Maintains Market Perform on Hippo Holdings, Raises Price Target to $26

During the last three months, 17 analysts shared their evaluations of BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $74.06, a high estimate of $105.00, and a low estimate of $43.00. Experiencing a 17.45% decline, the current average is now lower than the previous average price target of $89.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1745326872_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of BILL Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Andrew Bauch &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Underweight &#x7C; $43.00&#x7C;$57.00 &#x7C; 
&#x7C;Keith Weiss &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $65.00&#x7C;$100.00 &#x7C; 
&#x7C;Siti Panigrahi &#x7C;Mizuho &#x7C;Lowers &#x7C;Neutral &#x7C; $53.00&#x7C;$70.00 &#x7C; 
&#x7C;Clarke Jeffries &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $70.00&#x7C;$85.00 &#x7C; 
&#x7C;David Koning &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $55.00&#x7C;$82.00 &#x7C; 
&#x7C;Will Nance &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $60.00&#x7C;$90.00 &#x7C; 
&#x7C;Sanjay Sakhrani &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Market Perform &#x7C; $54.00&#x7C;$77.00 &#x7C; 
&#x7C;Alex Markgraff &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $70.00&#x7C;$85.00 &#x7C; 
&#x7C;Scott Berg &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $100.00&#x7C;$100.00 &#x7C; 
&#x7C;Will Nance &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $90.00&#x7C;$104.00 &#x7C; 
&#x7C;Ken Wong &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $90.00&#x7C;$110.00 &#x7C; 
&#x7C;Sanjay Sakhrani &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Market Perform &#x7C; $77.00&#x7C;$95.00 &#x7C; 
&#x7C;Alex Markgraff &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $85.00&#x7C;$115.00 &#x7C; 
&#x7C;Andrew Bauch &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Underweight &#x7C; $57.00&#x7C;$65.00 &#x7C; 
&#x7C;Joseph Vafi &#x7C;Canaccord Genuity &#x7C;Maintains &#x7C;Buy &#x7C; $105.00&#x7C;$105.00 &#x7C; 
&#x7C;Scott Berg &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $100.00&#x7C;$100.00 &#x7C; 
&#x7C;Clarke Jeffries &#x7C;Piper Sandler &#x7C;Maintains &#x7C;Overweight &#x7C; $85.00&#x7C;$85.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BILL Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of BILL Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of BILL Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of BILL Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BILL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BILL Holdings analyst ratings.</a>
<h2>Discovering BILL Holdings: A Closer Look</h2>
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
<h3>Financial Milestones: BILL Holdings's Journey</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: BILL Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 13.83%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: BILL Holdings's net margin is impressive, surpassing industry averages. With a net margin of 9.25%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.86%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): BILL Holdings's ROA excels beyond industry benchmarks, reaching 0.36%. This signifies efficient management of assets and strong financial health.
Debt Management: BILL Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.47, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BILL

What Analysts Are Saying About BILL Holdings Stock

Ratings for Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $27.17, a high estimate of $33.00, and a low estimate of $24.00. Observing a downward trend, the current average is 10.62% lower than the prior average price target of $30.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1745326862_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Pfizer by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Carter Gould &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Neutral &#x7C; $24.00&#x7C;- &#x7C; 
&#x7C;Trung Huynh &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $24.00&#x7C;$28.00 &#x7C; 
&#x7C;Asad Haider &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $25.00&#x7C;$32.00 &#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $33.00&#x7C;$33.00 &#x7C; 
&#x7C;Colin Bristow &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $28.00&#x7C;$29.00 &#x7C; 
&#x7C;Andrew Baum &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $29.00&#x7C;$30.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pfizer. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pfizer compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Pfizer's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Pfizer's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PFE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pfizer analyst ratings.</a>
<h2>Discovering Pfizer: A Closer Look</h2>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
<h3>Pfizer: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Pfizer showcased positive performance, achieving a revenue growth rate of 21.93% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Pfizer's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Pfizer's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Pfizer's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.19%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.72, Pfizer adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 6 Analyst Projections For Pfizer

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $214.5, a high estimate of $224.00, and a low estimate of $208.00. Highlighting a 0.23% decrease, the current average has fallen from the previous average price target of $215.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1745326851_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Gulfport Energy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Peyton Dorne &#x7C;UBS &#x7C;Announces &#x7C;Buy &#x7C; $215.00&#x7C;- &#x7C; 
&#x7C;Zach Parham &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $211.00&#x7C;$216.00 &#x7C; 
&#x7C;Doug Leggate &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $224.00&#x7C;$227.00 &#x7C; 
&#x7C;Zach Parham &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $208.00&#x7C;$202.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gulfport Energy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gulfport Energy compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Gulfport Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Gulfport Energy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GPOR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gulfport Energy analyst ratings.</a>
<h2>Delving into Gulfport Energy's Background</h2>
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets predominantly located in the Appalachia and Anadarko basins in the United States. Its principal properties are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
<h3>Breaking Down Gulfport Energy's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Gulfport Energy showcased positive performance, achieving a revenue growth rate of 8.28% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -95.82%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -14.49%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Gulfport Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.41, Gulfport Energy adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

United States Cellular Corporation 6.250% Senior Notes due 2069

Notizie

Ultime notizie per United States Cellular Corporation 6.250% Senior Notes due 2069 (NYSE:UZD) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO